Department of Neurosurgery, University of South Florida, Tampa, Florida, USA; Center for Cerebrovascular Diseases, Taihe Hospital, Shiyan, Hubei, China.
Department of Neurosurgery, University of South Florida, Tampa, Florida, USA.
World Neurosurg. 2019 Jul;127:492-499. doi: 10.1016/j.wneu.2019.04.116. Epub 2019 Apr 19.
The indications for mechanical thrombectomy (MT) have expanded since the American Heart Association/American Stroke Association reported its first guidelines for MT in 2013. Multiple subsequent randomized clinical trials of MT have proved its efficacy, including the DAWN (DWI [diffusion weighted imaging] or CTP [computed tomography perfusion] Assessment with Clinical Mismatch in the Triage of Wake-up and Late Presenting Strokes Undergoing Neurointervention with Trevo) and DEFUSE-3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke-3) trials. The current guidelines from the American Heart Association/American Stroke Association provide class I support for the use of MT for the following indications: 1) internal carotid artery (ICA)/M1 middle cerebral artery (MCA) occlusion, symptom onset <6 hours, National Institutes of Health Stroke Scale score of ≥6, Alberta Stroke Program Early Computed Tomography Score of ≥6; and 2) large vessel occlusions in the anterior circulation, symptom onset 6-16 hours, and meeting the DAWN or DEFUSE-3 eligibility criteria. Class IIa evidence is also available for the use of MT for large vessel occlusions in the anterior circulation, symptom onset 16-24 hours, and meeting other DAWN eligibility criteria. In clinical practice, these class I and IIa indications for MT have been well followed. However, many other potential indications are available, including 1) M2 or M3 MCA occlusion, symptom onset <6 hours; 2) Alberta Stroke Program Early Computed Tomography Score <6, ICA or M1 MCA occlusion, symptom onset <6 hours; 3) National Institutes of Health Stroke Scale score <6, ICA or M1 occlusion, symptom onset <6 hours; 4) tandem occlusions; and 5) posterior circulation occlusion <6 hours. The present review analyzed the available data to provide support for further prospective clinical trials regarding these potential indications.
自 2013 年美国心脏协会/美国中风协会首次报告机械取栓 (MT) 指南以来,MT 的适应证已经扩大。多项随后的 MT 随机临床试验证明了其疗效,包括 DAWN(DWI [弥散加权成像] 或 CTP [计算机断层灌注] 评估在醒后和延迟出现的中风患者的神经介入治疗中的临床不匹配筛选)和 DEFUSE-3(血管内治疗后影像学评估缺血性中风-3)试验。美国心脏协会/美国中风协会目前的指南为 MT 的以下适应证提供了 I 类支持:1)颈内动脉 (ICA)/M1 大脑中动脉 (MCA) 闭塞,症状发作<6 小时,国立卫生研究院中风量表评分≥6,阿尔伯塔中风计划早期计算机断层扫描评分≥6;2)前循环大血管闭塞,症状发作 6-16 小时,符合 DAWN 或 DEFUSE-3 入选标准。对于前循环大血管闭塞,症状发作 16-24 小时,符合其他 DAWN 入选标准,也有 IIa 级证据支持使用 MT。在临床实践中,这些 MT 的 I 类和 IIa 类适应证得到了很好的遵循。然而,还有许多其他潜在的适应证,包括 1)M2 或 M3 MCA 闭塞,症状发作<6 小时;2)阿尔伯塔中风计划早期计算机断层扫描评分<6,ICA 或 M1 MCA 闭塞,症状发作<6 小时;3)国立卫生研究院中风量表评分<6,ICA 或 M1 闭塞,症状发作<6 小时;4)串联闭塞;5)后循环闭塞<6 小时。本综述分析了现有数据,为进一步开展关于这些潜在适应证的前瞻性临床试验提供支持。